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Background: Long-term complications and a case mortality rate of 7.5% make meningitis caused by Streptococcus
pneumoniae a serious clinical threat. In 2006, a general pneumococcal conjugate vaccination (PCV)
recommendation was issued for all children under 2 years in Germany. Here, we investigate serotype changes in
meningitis cases after this vaccine recommendation.
Methods: The German National Reference Center for Streptococci (NRCS) has conducted surveillance for invasive
pneumococcal disease (IPD) in Germany since 1992. Pneumococcal isolates were serotyped by the Neufeld’s
Quellung reaction and antibiotic susceptibility was tested using the broth microdilution method.
Results: Of 22,204 IPD isolates sent to the NRCS from July 1992 to June 2013, 3,086 were meningitis cases.
Microbiological and statistical investigations were performed to characterize and quantify all meningitis cases,
focusing on changes reflecting implementation of the national PCV recommendation. 1,766 isolates (57.2% of
meningitis cases) were from adults (≥16 years) and 1,320 isolates (42.8%) originated from children (<16 years).
Overall, the leading serotypes were 14 (9.7%), 7F (7.8%), 3 (6.9%), 19F (5.7%) and 23F (5.0%). Among children,
serotypes 14 (16.2%), 7F (8.9%) and 19F (7.1%) were most common, whereas among adults, serotypes 3 (9.6%),
7F (6.9%), 22F (5.0%), 23F (4.9%) and 14 (4.8%) were most prevalent. After the introduction of general PCV7/10/13
vaccination a significant decrease for most vaccine serotypes was observed. Generally, the differences in antibiotic
nonsusceptibility between children <16 years and adults ≥16 were low. For macrolides in the pre-PCV7 period, a
significantly higher proportion of resistant isolates was found in children (25.1%), compared to the post-vaccination
period (9.7%; p<0.0001).
Conclusions: Implementation of the pneumococcal conjugate vaccines broadly reduced vaccine-type meningitis
cases. Changes in serotype prevalence must be continuously monitored to observe future trends concerning
pneumococcal meningitis.
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Streptococcus pneumoniae is among the most important
pathogens in bacterial meningitis worldwide [1]. Menin-
gitis occurs in all age groups, with the peak of incidence
during the first two years of life [2,3], especially during
months 2–12 [3-5]. Case fatality rates in pneumococcal* Correspondence: mimoehl@ukaachen.de
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are higher in adults than in children [6]. Among children
in Germany, mortality rates of 7.5% have been reported
[7]. Despite adequate antibiotic treatment, about half of
the survivors show substantial long term morbidity, as
reflected by persisting neurological deficits comprising
cognitive impairment, seizures, hearing loss, and other
handicaps [8]. Early clinical complications, such as life-
threatening increase of intracranial pressure, and late
disease consequences in survivors, who frequently suffer
from sustained neuropsychological impairment, contributehis is an Open Access article distributed under the terms of the Creative
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nisms of neurotoxicity are still largely unknown. Clearly,
the capsular polysaccharide of S. pneumoniae contrib-
utes to pathogenicity [9], and pneumococcal toxins
(such as pore-forming pneumolysin or hydrogen per-
oxide) as well as excessive host immune responses have
been suggested as harmful influencing factors [10,11].
Indeed, recent studies have suggested the use of corti-
costeroids to limit excessive inflammatory reactions within
the CNS [12]. However, regarding Streptococcus pneu-
moniae, regional epidemiologic features may affect the
possible therapeutic benefit of corticosteroids [13], em-
phasizing the relevance of a systematic description of the
respective isolates.
In Germany, a general recommendation for pneumo-
coccal conjugate vaccination for all children under two
years of age was issued in July 2006. Initially, vaccination
was performed with Prevenar® (PCV7). Beginning in April
2009, with licensing of higher-valent vaccine formulations,
Synflorix® (PCV10) was used, and Prevenar 13® (PCV13),
which replaced PCV7, was introduced in December 2009.
All vaccination costs are fully reimbursed by health insur-
ance companies and the choice of the vaccine lies with the
parents/pediatrician. Uptake of the PCV7 vaccine was
high and reached 80% one year after the vaccination rec-
ommendation. Uptake of PCV10 has been low, reaching
20% of total doses only in 2009, and decreasing afterwards.
Current childhood vaccine uptake lies above 90%, of
which 96% is PCV13. The 23-valent pneumococcal poly-
saccharide vaccine (Pneumovax 23®) is recommended for
adults 60 years and older, and for at-risk patients ≥2 years
of age.
Several studies have reported frequencies of pneumo-
coccal serotypes and pneumococcal vaccine coverage in
invasive pneumococcal disease (IPD), but little informa-
tion is available on serotype distribution among meningitis
cases from Germany. Experience from other European
countries as reflected by the 2011 report of the ECDC as
well as by separate studies from Spain [14], England and
Wales [15,16], and The Netherlands [17,18] suggest a pro-
found impact of PCV7 vaccination programs on the inci-
dence of pneumococcal meningitis.
Moreover, in light of the emergence of antibiotic-resistant
strains, the choice of first-line treatment represents
an important epidemiological issue. Finally, the pos-
sible impact of the general recommendation of pneumo-
coccal conjugate vaccination for children <2 years,
introduced in Germany in July 2006, has not yet been
investigated.
Here we analyzed serotype distribution, theoretical sero-
type coverage of pneumococcal vaccines, and antimicro-
bial susceptibility of all meningitis isolates that were sent
to the German National Reference Center for Streptococci
(NRCS) from July 1, 1992 to June 30, 2013.Methods
Study design
The NRCS has conducted surveillance for IPD in Germany
since 1992. In this study, a population- and laboratory-
based approach was used to collect data about meningitis
among children (<16 years) and adults (≥16 years) caused
by Streptococcus pneumoniae. Isolates were sent to the
NRCS by diagnostic microbiological laboratories through-
out Germany on a voluntary basis [19].
Invasive pneumococcal disease cases were defined as
S. pneumoniae isolates from blood, cerebrospinal fluid
(CSF) or any other normally sterile body fluid. Meningitis
was primarily defined by the isolation of S. pneumoniae
from cerebrospinal fluid (CSF). However, when men-
ingitis was specified as the definite clinical diagnosis on
the case form, and the samples originated from blood,
these samples were also considered to represent men-
ingitis cases, even if CSF from these patients was not
received.
Microbiological diagnostic laboratories from all over
Germany were requested to send isolates of invasive
pneumococcal disease to the NRCS. Currently, over 300
laboratories participate, including the large, nationally-
operating commercial labs. Over the years, the surveil-
lance system has been improved. In 2001, surveillance for
adults was enhanced in North Rhine-Westphalia (22%
of German population), as well as in Bavaria and Saxony
in 2006. On each occasion, all laboratories in the re-
spective federal states were approached and asked to
send in isolates. In 2007, a web-based surveillance system
(Pneumoweb) was set up in collaboration with the Robert
Koch Institute. Pneumoweb enables the laboratories to
report a case of IPD via an online reporting system,
and at the same time, print the reported information
to accompany the IPD isolate, which can then be sent
to the NRCS. The web-based system resulted in a large
increase in reported cases for adults, whereas the amount
of cases for children remained at the same high level.
Cases were grouped per pneumococcal season (from
July to June of consecutive years) because of known in-
fection clusters during winter.
Microbiological investigations
Isolates were identified using standard procedures includ-
ing bile solubility and optochin sensitivity. Pneumococcal
isolates were serotyped by the Neufeld’s Quellung reaction
using type- and factor-specific antisera (Statens Serum
Institut, Copenhagen, Denmark). Minimal inhibitory
concentrations (MIC) testing was performed using the
broth microdilution method as recommended by the
Clinical and Laboratory Standards Institute (CLSI) [20]
and current CLSI interpretative criteria were used to de-
fine antimicrobial resistance. Macrolide resistance was
investigated using erythromycin or clarithromycin. To
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mg/l) and cefotaxime (≤0.5 mg/l, 1 mg/l, ≥2 mg/l) resist-
ance, parenteral meningitis breakpoints were used. Strepto-
coccus pneumoniae ATCC 49619 was used as a control
strain.
Statistical methods
Statistical calculations were performed using R (version
3.0.1, 2013) and the Analysis ToolPak in MS Excel. Fisher’s
exact test was used to compare differences in proportion
and two-sample t-tests were used to compare differences
in percent distributions. All p-values reported are two-
sided. Adjustments for multiple comparisons were per-
formed using the Dunn-Šidák correction, and the resulting
β values, which determine the significance threshold, are
included in the table legends. The season of vaccine intro-
duction, 2006–07, was considered a transition period and
taken out of consideration in the analyses.
Ethics and consent
An ethical approval or patients’ consent was not required
since the study only includes microbiological samples sent
to the German National Reference Center for Streptococci
on an anonymized basis by the sending microbiological
laboratories, and did not involve human subjects or
material.
Results
A total of 3,086 isolates from meningitis cases were col-
lected, with 1,766 isolates (57.2%) from adults and 1,320
isolates (42.8%) from children. The mean age was 34.0
years (median 37 years; range 0–99 years). More isolates
were obtained from male patients (55.0%) than from fe-
male patients (43.6%). For 1.4% of isolates no information
on gender was available. The mean age among children
was 2.8 years (median 1 year) and among adults 57.2 years
(median 59 years). The isolates were obtained from
CSF (2565) and blood (521). The absolute number of
meningitis cases reported to NRCS per pneumococcal
season varied between 8 and 121 (mean 62.9; median 66) for
children, and between 26 and 183 (mean 84.1; median 56)
for adults.
As expected, children were disproportionately more often
affected by meningitis in the first years of life (Figure 1),
and the younger the child, the higher the risk: 484 cases
occurred within the first year of life (15.7% of all cases),
followed by 252 (8.2%), 116 (3.8%), 103 (3.3%), 69 (2.2%)
and 44 (1.4%) cases for the next years of age, respectively.
After the introduction of conjugate vaccination, the pro-
portion of meningitis cases among all reported 22,204 IPD
cases changed for both children and adults. Among chil-
dren, the percentage of meningitis showed a slightly de-
creasing trend (slope: −0.17) in the pre-PCV7 period
(1997/98-2005/06; the first five seasons were taken out ofthis analysis because of the low number of reported cases).
After vaccine introduction (2007/08-2012/13), a similar
decreasing trend (slope: −0.16) was observed. The post-
PCV7 trendline shows a significant drop when compared
to the projected pre-PCV7 trendline (p<0.0001). Among
adults, a decreasing trend in meningitis percentage was
found in the pre-PCV7 period as well (1992/93-2005/06,
slope: −0.32). Post-vaccination the decrease was also
stronger (2007/08-2012/13, slope: −0.79), and the com-
parison between the projected pre-PCV7 trendline and
the post-PCV7 trendline also reached statistical signifi-
cance (p<0.0001) (Figure 2a and b).
Data on serotypes were available for 3,051 isolates
(98.9%), which were included for further analysis. The
number of isolates from meningitis cases according to
age groups (<2 years, 2–4 years, 5–15 years, 16–40 years,
41–64 years and ≥ 65 years) and PCV7 vaccine-type,
PCV13-non-PCV7 vaccine-type (i.e. this includes only the
six additional serotypes present in PCV13, as compared to
PCV7) and non-PCV13 vaccine-type is shown in Figure 3.
Only pneumococcal seasons with a total number of ≥ 100
meningitis cases with information on serotypes available
were included in the figure (2000/01-2012/13). A signifi-
cant decline of PCV7 serotypes (p<0.0001) in the seasons
following the introduction of the pneumococcal conjugate
vaccines was observed for all children’s and adults’ age
groups. The decline continued throughout the higher
valent-PCV period (2009/10 -2012/13).
PCV13-non-PCV7 serotypes increased in all age groups
after PCV7 introduction (2006/07-2008/09), with age
groups <2 years and from 41–64 reaching statistical sig-
nificance (p<0.0001 and p = 0.0108, respectively). All age
groups showed a decrease after the start of higher-valent
vaccination (2009/10-2012/13), with age groups <2 years
old and 15–40 years old reaching statistical significance
(p = 0.0051 and p = 0.0439, respectively).
The serotype distribution among pneumococcal men-
ingitis isolates is shown in Table 1 through Table 2.
Overall, the leading serotypes were 14 (9.7%), 7F (7.8%),
3 (6.9%), 19F (5.7%) and 23F (5.0%). Among children,
serotypes 14 (16.2%), 7F (8.9%) and 19F (7.1%) were
most common, whereas among adults, serotypes 3 (9.6%),
7F (6.9%), 22F (5.0%), 23F (4.9%) and 14 (4.8%) were most
prevalent.
When considering only the pre-PCV7 period (Table 1),
the most common serotypes in children were 14 (23.7%),
19F (9.3%), 6B (9.1%), 18C (8.5%), and 23F (6.8%); for
adults, the most common pre-PCV7 serotypes were 23F
(8.9%), 14 (7.9%), 4 (7.1%), 3 (7.1%), and 19F (6.0%).
Of the most prevalent serotypes before vaccination,
14 (23.7% in children vs. 7.9% in adults, p<0.0001), and
18C (8.5% vs. 2.8%, p<0.0001) were significantly more
common in children (age <16 years). Among adults, sero-
types 3 (7.1% vs. 1.9%, p<0.0001), 9V (5.6% vs. 1.7%, p =
Figure 1 Age distribution of reported meningitis cases in Germany per 100,000 inhabitants per age group per year from 1992/93 to
2012/13 (n = 3,116) based on a population of 82,437,995 in 2005 (http://www.destatis.de).
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cantly more prevalent.
The post-PCV7 period (Table 3) already showed a shift
in serotype distribution with serotypes 7F (16.7%), 18C
(7.9%), 1 (7.0%), 3 (4.8%), 6A (4.8%), and 14 (4.8%) be-
coming dominant in children, while 3 (12.8%), 7F (6.9%),
22F (6.3%), 6A (5.4%), 10A (5.0%) and 19A (5.0%) led
among adult meningitis cases. In the post-PCV7 period,
serotypes 7F (16.7% vs 6.9%, p = 0.0001) and 18C (7.9%
vs 2.5%, p = 0.0011) were significantly more common in
children than in adults, and serotype 3 remained sig-
nificantly more common in adults (12.8% vs 4.8%, p =
0.0007).
The post-PCV13 period (Table 2), which includes
the higher-valent formulations of PCV, shows further
changes to the serotype distribution in meningitis cases.
Leading serotypes from children in this period were 7F
(8.8%), 19A (7.2%), 10A (7.2%), 23B (7.2%), and 12F
(6.2%); in adults, 23B (9.6%), 3 (9.4%), 7F (9.1%), 19A
(6.6%), 22F (5.9%) and 12F (5.9%) occurred most often. In
the post-PCV13 period, there were no serotypes that were
significantly more prevalent in either children or adults.
When comparing the serotype distribution in the pre
PCV7-period (1992/93-2005/06), the post PCV7-period
(2007/08-2009/10) and the post PCV13-period (2010/11-
2012/13), several changes were observed. Among children
(Table 4), serotypes 4, 6B, 14, 19F and 23F decreased sig-
nificantly when comparing the pre- and post- vaccination
periods (pre-PCV7 vs. post-PCV7 + post-PCV13, p-values
less than β = 0.000732493). Among the six additional se-
rotypes included in PCV13, only serotype 6A showed a
decrease post vaccination, although it does not reach stat-
istical significance. The comparison of the pre-PCV7 with
the post-PCV7 period, however, shows that serotypes 1, 3,6A, 7F and 19A all increased in the post-PCV7 period,
with only serotype 7F reaching statistical significance, ac-
cording to our very stringent criteria. However, comparing
the post-PCV7 period with the post-PCV13 period showed
a decrease in serotypes 1, 6A and 7F, with only serotype 1
reaching statistical significance. Non-PCV13 serotypes
which increased significantly after the introduction of
conjugate vaccines were 12F, 15C, 22F, 23B and 35B.
Among adults (Table 5), a significant decrease of sero-
types 4, 6B, 9V, 14, and 23F was observed after the start
of childhood conjugate vaccination. Serotypes 1, 3, 7F and
19A increased post-PCV7 as compared to pre-PCV7, but
not significantly. When comparing the post-PCV13 period
to the post-PCV7 period, serotypes 1, 3 and 6A appear
to decrease again, with serotype 6A approaching stat-
istical significance. Serotypes 7F and 19A still showed
an increase post-PCV13, but less pronounced (higher
p-values). Non-PCV13 serotypes which increased among
adults following the introduction of childhood-vaccination
were 6C, 12F, 15B, 15C, 22F, 23A, 23B and 35B. Only the
increase of serotype 23B reached statistical significance
(p<0.0001).
In the pre-PCV7 era, theoretical serotype coverage of
PCV7 for children was 62.5%, and for PCV10 and PCV13,
the serotype coverage was 72.2% and 81.0%, respectively.
The theoretical coverage of PPV23 was 85.1%. Among
adults, coverage for the 7-, 10-, 13- and 23-valent vaccines
was 43.5%, 49.9%, 65.5% and 80.7%, respectively. PCV13-
non-PCV7 serotypes accounted for 18.4% and 22.0% of all
serotypes in children and adults respectively. For all vac-
cines types, the coverage was higher among children than
among adults (Table 6).
During the post PCV7- and post-PCV13 period, the vac-
cine coverage for the 7-, 10-, 13- and 23-valent vaccines
Figure 2 Number of IPD isolates sent to the NRCS and number of pneumococcal meningitis cases contained. a Number of IPD isolates
from children sent to the NRCS (n = 3,892) and number of pneumococcal meningitis cases contained (n = 1,320) per pneumococcal season from
1992/93 to 2012/13 (left Y-axis). The percentage of meningitis cases is indicated on the right Y-axis and trendlines are added for the pre- (1997/
98-2005/06, slope −0.17) and the post-vaccination era (2007/08-2012/13, slope −0.16). The difference between the trendlines was highly significant
(p<0.0001). b Number of IPD isolates from adults sent to the NRCS (n = 18,312) and number of pneumococcal meningitis cases contained (n = 1,766)
per pneumococcal season from 1992/93 to 2012/13 (left Y-axis). The percentage of meningitis cases is indicated on the right Y-axis and trendlines are
added for the pre- (1997/98-2005/06, slope −0.32) and the post-vaccination era (2007/08-2012/13, slope −0.79). Both the overall proportion and
difference between the trendlines were highly significant (p<0.0001).
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and 6.5%, 13.7%, 25.2% and 59.0% for adults in 2012/13
(PCV13-non-PCV7 serotypes decreased to 11.5% and
18.7% respectively). The decrease in coverage during the
post-vaccination period was statistically significant for all
three PCVs both for children and adults. For PCV13-non-
PCV7 serotypes, there was an increase in the post-PCV7
period when compared to the pre-PCV7 period (reaching
statistical significance for children, and near statistical sig-
nificance for adults), followed by a decrease in childrenand adults in the post-PCV13 period. Since cross reactive
serotypes were not included in the calculation, coverage
information strictly refers to the serotypes included in the
vaccines.
Detailed results of the antimicrobial susceptibility test-
ing are shown in Table 7. Generally, the differences in
antibiotic susceptibility between children < 16 years and
adults ≥ 16 years were low. Macrolides showed a signifi-
cant difference when comparing rates of resistance in chil-
dren (19.8%) against rates of resistance in adults (10.8%;
Figure 3 Isolates from meningitis cases from 2000/01 to 2012/13 (n = 2,508) according to age groups and PCV7 vaccine-type (red),
PCV13-non-PCV7 vaccine-type (blue) or non-PCV13 vaccine-type (green). The number of all meningitis cases is shown in black. The Y-axes
of the figure are adjusted to the number of meningitis cases in each age group.
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ing the pre- and post-vaccination periods in children
(25.1% vs. 9.7%; p<0.0001). Following vaccine introduc-
tion, the difference between resistant isolates in children
and adults diminished and lost statistical significance
(post-PCV7: p = 0.6820, post PCV13: p = 0.8803), due to
decreasing resistance rates in the post-vaccination period
in both age groups.
Discussion
Here we present the results of 20 years of pneumococcal
meningitis surveillance in Germany.
Some limitations must be considered when interpret-
ing the results of this study. First, the isolates were sent
by the participating laboratories on a voluntary basis, as
IPD is not a notifiable disease in Germany which makes
the system more vulnerable to under-reporting. Cer-
tainly, this would affect non-meningitis IPD more than
meningitis, since the latter is a more severe condition.
Furthermore, the systematic sampling of invasive isolates
from adults (1992) and children (1997) was taken up at
different times, and included population-based studies in
three German federal states: North Rhine-Westphalia,
started in 2001; Bavaria, started in 2006; Saxony, started
in 2006. Moreover, the structure of the surveillance pro-
ject has been continuously improved over the 20 years
of the study period, particularly after the general recom-
mendation of pneumococcal conjugate vaccination [21],
which led to increased disease awareness by both clinical
microbiologists and pediatricians. The introduction of a
web-based reporting system, Pneumoweb, in 2007 alsocontributed to an increased number of reported cases of
IPD among adults, from 200–500 cases per season to
over 2000 cases per season.
As expected [22], we observed a peak incidence of
pneumococcal meningitis in patients younger than two
years. For both children and adults, the frequency of men-
ingitis, measured as a fraction of total IPD, has been de-
creasing since the start of our surveillance. The fact that
this decrease became stronger post PCV7-vaccination
may indicate a beneficial effect of vaccination on the
severity of pneumococcal disease: apparently, the se-
rotypes remaining after vaccination are less capable of
causing meningitis. The general decrease in frequency
of pneumococcal meningitis among children since the
general recommendation for PCV vaccination has
been described by our group previously [23]. The here-
reported significant decrease of meningitis caused by
PCV7 and PCV13 serotypes post-vaccination in chil-
dren <2 years of age shows the effectiveness of these vac-
cinations in this age group. As we observed a decrease in
PCV7 and PCV13 serotypes among older children and
adults as well, our data suggest a strong herd protection
effect.
Our data are in line with previous observations [2,24,25]
and underline the efficacy of vaccination strategies to
strengthen herd protection [26]. The apparent increase of
meningitis cases among adults since 2006/07 is most likely
due to enhanced surveillance, as described in our study
limitations above.
According to our study, in the pre-PCV7 period, sero-
type 14 was the most prevalent serotype among meningitis
Table 1 Serotype distribution of pneumococcal meningitis
isolates in Germany among children <16 years, adults ≥16
years, and the overall population (1992/93-2005/06,
n = 1382)
Serotype Percent of
isolates,
children
Percent of
isolates,
adults
P value Percent of
isolates,
overall
No of
isolates,
overall
14 23.7 7.9 <0.0001 17.5 232
19F 9.3 6.0 0.0260 8.2 108
6B 9.1 5.1 0.0050 7.7 102
18C 8.5 2.8 <0.0001 6.3 83
23F 6.8 8.9 0.1562 8.1 107
7F 6.3 4.6 0.1945 5.8 77
6A 4.4 5.5 0.3783 5.1 67
4 3.5 7.1 0.0028 5.3 70
1 2.8 1.7 0.2063 2.4 32
19A 2.4 3.0 0.6153 2.8 37
3 1.9 7.1 <0.0001 4.4 58
10A 1.8 3.6 0.0406 2.7 36
9V 1.7 5.6 0.0001 3.6 47
8 1.3 3.1 0.0221 2.2 29
33F 1.0 1.7 0.3452 1.4 18
11A 0.9 2.1 0.0686 1.5 20
15B 0.9 1.0 1.0000 1.0 13
9N 0.8 2.3 0.0220 1.5 20
22F 0.6 3.5 0.0002 2.0 26
15C 0.6 0.3 0.4771 0.5 7
23A 0.5 1.7 0.0547 1.1 14
6C 0.5 0.5 1.0000 0.5 7
5 0.5 0.2 0.3934 0.4 5
12F 0.4 1.7 0.0220 1.0 13
17F 0.4 1.0 0.1912 0.7 9
23B 0.3 0.5 0.6588 0.4 5
20 0.3 0.3 1.0000 0.3 4
2 0.1 0.3 0.5845 0.2 3
35B 0.1 0.0 1.0000 0.1 1
others 8.5 10.9 0.1402 10.0 132
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0.001708316).
Significant P values are printed in bold.
Table 2 Serotype distribution of pneumococcal meningitis
isolates in Germany among children <16 years, adults ≥16
years, and the overall population (2010/11-2012/13, n = 638)
Serotype Percent of
isolates,
children
Percent of
isolates,
adults
P value Percent of
isolates,
overall
No of
isolates,
overall
7F 8.8 9.1 1.0000 8.8 56
19A 7.2 6.6 0.7289 6.6 42
10A 7.2 4.0 0.0737 4.9 31
23B 7.2 9.6 0.4467 8.6 55
12F 6.2 5.9 0.8541 5.8 37
3 5.7 9.4 0.2035 8.0 51
15C 5.7 2.8 0.1029 3.6 23
22F 4.1 5.9 0.5604 5.2 33
35B 4.1 1.2 0.0273 2.0 13
19F 2.6 3.3 0.8044 3.0 19
11A 2.6 4.0 0.4894 3.4 22
33F 2.6 1.9 0.5481 2.0 13
6B 2.1 0.7 0.2081 1.1 7
8 2.1 3.3 0.6054 2.8 18
15B 2.1 3.0 0.7897 2.7 17
9N 1.5 3.0 0.4139 2.5 16
6C 1.5 2.1 1.0000 1.9 12
23A 1.5 4.2 0.1462 3.3 21
18C 1.0 2.1 0.5180 1.7 11
23F 0.5 1.2 0.6731 0.9 6
1 0.5 2.1 0.2966 1.6 10
5 0.5 0.0 0.3041 0.2 1
6A 0.5 1.9 0.2892 1.4 9
4 0.0 0.7 0.5571 0.5 3
9V 0.0 0.5 1.0000 0.3 2
14 0.0 1.9 0.1140 1.3 8
2 0.0 0.0 1.0000 0.0 0
17F 0.0 0.7 0.5571 0.5 3
20 0.0 0.9 0.3197 0.6 4
others 22.2 12.2 0.0010 14.9 95
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0.001708316).
Significant P values are printed in bold.
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and 18C. Serotype 14 has been described to be the most
frequent serotype in meningitis in Italy, Belgium and
Brazil, and in Germany, among both children and adults
[27-31]. Serogroups 6 and 23 have been previously de-
scribed to be among the major players in pneumococcal
meningitis [6,27-29]. In the post-PCV7- and post-PCV13
periods, the serotype distribution drastically changed, with
the vaccine serotypes loosing importance.In the pre-PCV7 period, serotypes significantly more
common in children in our study were serotypes 14 and
18C. Serotype 14 is among the serotypes often defined
as ‘pediatric serotypes’ (6B, 9V, 14, 19F, and 23F) [32],
and serotype 18C is among the ten serotypes reported to
be responsible for about 80% of IPD in children younger
than 5 years [33]. Four of these six serotypes were among
the most common in IPD among German children <16
years in the pre-vaccination period (serotype 14, 26.4%;
6B, 7.7%; 19F, 7.1%, 18C, 6.2%), as recently published by
our group [30]. In the post-PCV7 period 7F appeared as
Table 3 Serotype distribution of pneumococcal meningitis
isolates in Germany among children <16 years, adults ≥16
years, and the overall population (2007/08-2009/10, n = 750)
Serotype Percent of
isolates,
children
Percent of
isolates,
adults
P value Percent of
isolates,
overall
No of
isolates,
overall
7F 16.7 6.9 0.0001 9.6 74
18C 7.9 2.5 0.0011 4.0 31
1 7.0 2.9 0.0149 4.0 31
14 4.8 2.7 0.1817 3.3 25
3 4.8 12.8 0.0007 10.2 78
6A 4.8 5.4 0.8593 5.1 39
6B 4.4 1.1 0.0100 2.1 16
22F 4.4 6.3 0.3927 5.6 43
19A 4.0 5.0 0.7066 4.6 35
15C 4.0 1.3 0.0288 2.1 16
10A 3.5 5.0 0.4487 4.4 34
19F 2.2 4.8 0.1081 3.9 30
23F 2.2 3.4 0.4908 3.0 23
8 2.2 2.7 0.8052 2.5 19
12F 2.2 2.7 0.8052 2.5 19
15B 1.8 3.1 0.4595 2.6 20
23A 1.8 2.9 0.4569 2.5 19
9N 1.3 2.9 0.2992 2.3 18
17F 1.3 0.6 0.3740 0.8 6
33F 1.3 1.9 0.7640 1.7 13
9V 0.9 2.3 0.2484 1.8 14
6C 0.9 2.9 0.1126 2.2 17
35B 0.9 1.3 0.7305 1.2 9
4 0.4 2.3 0.1232 1.7 13
11A 0.4 2.1 0.1196 1.6 12
23B 0.4 2.1 0.1196 1.6 12
5 0.0 0.2 1.0000 0.1 1
2 0.0 0.0 1.0000 0.0 0
20 0.0 0.6 0.5575 0.4 3
others 13.2 9.6 0.1564 10.4 80
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0.001708316).
Significant P values are printed in bold.
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the post-PCV13 period there were no serotypes that were
significantly more prevalent in either children or adults.
In the pre-vaccination period, among adults, serotypes
23F, 14, 3 and 4 were predominant, three of which were
among the more common in IPD among adults ≥16 years
in Germany (serotype 14, 14.3%; 3, 9.2%; 23F, 5.6%) [31].
Also here, the serotype distribution drastically changed
in the post-PCV7- and post-PCV13 periods, with the
vaccine serotypes loosing importance. In the post-PCV7period only serotype 3 remained significantly more preva-
lent among adults.
In the pre-PCV7 period, serotypes 3, 9V and 22F were
significantly more common in adults than in children
and can be considered ‘adult serotypes’.
A reduction in PCV7 vaccine serotypes was observed
post-PCV7-vaccination in both children and adults but
did not reach statistical significance in either category for
every single PCV7 serotype. Among children, serotypes
9V (p = 0.1015) and 18C (p = 0.0186) both decreased,
but the p-values did not meet our very stringent criteria.
Among adults, the same was true for 19F (p = 0.0892)
whereas 18C showed no significant change at all (p =
0.5094). This could indicate a reservoir for this sero-
type among adults. The increase of serotypes included
in the higher-valent pneumococcal conjugate vaccines
in both children and adults in the post-PCV7 period
shows the rationale for introduction of these vaccines
in Germany (PCV10: April 2009, PCV13 December
2009). In the post-PCV13 period, a decrease in serotypes
1, 6A and 7F in children, and in serotypes 1, 3 and 6A in
adults was observed. Additionally, the observed increase
in serotype 19A in the post-PCV7 period was much less
pronounced in the post-PCV13 period. These shifts in
serotype prevalence show that the increase in non-vaccine
serotypes after introduction of PCV7 in childhood vaccin-
ation was, for a large part, caused by the serotypes that are
included in PCV13, and thus, that the introduction of
PCV13 has reversed these trends.
However, there is an increase of serotypes not included
in any conjugate vaccine (and many serotypes not in the
polysaccharide vaccine). As discussed before [24], non-
vaccine types have emerged after 2006. This pattern has
been recently reported in the northern region of France,
where introduction of the PCV7 vaccine showed success
in the beginning, but was followed by a rebound of men-
ingitis incidence to the pre-vaccination era [34]. As a
substantial proportion of cases were due to serotypes
covered by the PCV13 vaccine, the authors recommended
the near-term introduction of higher-valent vaccines. Pre-
vious studies in children indicate that pneumococcal men-
ingitis caused by non-PCV7 serotypes was associated with
a lower lethality than PCV7 serotypes, while the incidence
of neurological deficits was the same in both groups
[35]. Moreover, Nigrovic and colleagues confirmed that
S. pneumoniae is still the responsible pathogen in a sub-
stantial proportion of patients with bacterial meningitis
in childhood, with half of them caused by non-PCV7-
vaccine serotypes [36]. Obviously, serotypes not covered
by pneumococcal conjugate vaccines have to be regarded
as a persisting clinical threat, requiring increased efforts
for the implementation of vaccines with broader coverage.
Comparing the theoretical serotype coverage for the
pneumococcal vaccines among meningitis cases, and for
Table 4 Most common serotypes among pneumococcal meningitis isolates in Germany among children <16 years
(1992/93-2005/06, n = 777; 2007/08-2009/10, n = 227; 2010/11-2012/13, n = 194)
Children 1992/93-
2005/06
2007/08-
2009/10
2010/11-
2012/13
P values
Serotypes (n) % (n) % (n) % Pre PCV 7 vs post PCV7+13 Pre PCV7 vs post PCV7 Post PCV7 vs post PCV13
4 27 3.5 1 0.4 0 0.0 0.0002↓ 0.0105↓ 1.0000
6B 71 9.1 10 4.4 4 2.1 0.0001↓ 0.0188↓ 0.2755↓
9V 13 1.7 2 0.9 0 0.0 0.1015↓ 0.5414↓ 0.5019↓
14 184 23.7 11 4.8 0 0.0 <0.0001↓ <0.0001↓ 0.0012↓
18C 66 8.5 18 7.9 2 1.0 0.0186↓ 0.8918↓ 0.0008↓
19F 72 9.3 5 2.2 5 2.6 <0.0001↓ 0.0002↓ 1.0000
23F 53 6.8 5 2.2 1 0.5 <0.0001↓ 0.0088↓ 0.2241↓
PCV 7 486 62.5 52 22.9 12 6.2 <0.0001↓ <0.0001↓ <0.0001↓
1 22 2.8 16 7.0 1 0.5 0.3062↑ 0.0087↑ 0.0007↓
5 4 0.5 0 0.0 1 0.5 0.6624↓ 0.5799↓ 0.4608↑
7F 49 6.3 38 16.7 17 8.8 0.0001↑ <0.0001↑ 0.0197↓
PCV10 561 72.2 106 46.7 31 16.0 <0.0001↓ <0.0001↓ <0.0001↓
3 15 1.9 11 4.8 11 5.7 0.0025↑ 0.0287↑ 0.8269↑
6A 34 4.4 11 4.8 1 0.5 0.2106↑ 0.7184↑ 0.0074↓
19A 19 2.4 9 4.0 14 7.2 0.0084↑ 0.2504↑ 0.1961↑
PCV13 629 81.0 137 60.4 57 29.4 <0.0001↓ <0.0001↓ <0.0001↓
2 1 0.1 0 0.0 0 0.0 1.0000 1.0000 1.0000
8 10 1.3 5 2.2 4 2.1 0.3323↑ 0.3497↑ 1.0000
9N 6 0.8 3 1.3 3 1.5 0.3624↑ 0.4309↑ 1.0000
10A 14 1.8 8 3.5 14 7.2 0.0021↑ 0.1255↑ 0.1230↑
11A 7 0.9 1 0.4 5 2.6 0.3969↑ 0.6912↓ 0.0991↑
12F 3 0.4 5 2.2 12 6.2 <0.0001↑ 0.0174↑ 0.0472↑
15B 7 0.9 4 1.8 4 2.1 0.1734↑ 0.2811↑ 1.0000
17F 3 0.4 3 1.3 0 0.0 0.4295↑ 0.1329↑ 0.2528↓
20 2 0.3 0 0.0 0 0.0 0.5438↓ 1.0000 1.0000
22F 5 0.6 10 4.4 8 4.1 <0.0001↑ 0.0003↑ 1.0000
33F 8 1.0 3 1.3 5 2.6 0.2906↑ 0.7189↑ 0.4793↑
PPV23 729 93.8 199 87.7 137 70.6 <0.0001↓ 0.6504↓ <0.0001↓
6C 4 0.5 2 0.9 3 1.5 0.2917↑ 0.6226↑ 0.6653↑
15C 5 0.6 9 4.0 11 5.7 <0.0001↑ 0.0009↑ 0.4930↑
23A 4 0.5 4 1.8 3 1.5 0.0588↑ 0.0826↑ 1.0000
23B 2 0.3 1 0.4 14 7.2 <0.0001↑ 0.5369↑ 0.0002↑
35B 1 0.1 2 0.9 8 4.1 0.0002↑ 0.1300↑ 0.0492↑
others 66 8.5 30 13.2 43 22.2 <0.0001↑ 0.0388↑ 0.0201↑
NVT 82 10.6 48 21.1 82 42.3 <0.0001↑ 0.0001↑ <0.0001↑
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0.000732493). Arrows indicate increasing or decreasing percentage of serotypes post vaccination.
PCV7: serotypes 4, 6B, 9V, 14, 18C, 19F, 23F; PCV10: PCV7 + serotypes 1, 5, 7F; PCV13: PCV10 + serotypes 3, 6A, 19A; PPV23: PCV13 + serotypes 2, 8, 9N, 10A, 11A,
12F, 15B, 17F, 20, 22F, 33F, but without serotyp 6A; NVT: non-vaccine types, i.e. serotypes not included in any of the above mentioned vaccines.
Significant P values are printed in bold.
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vaccination, the coverage was similar both for children
(7v, 62.5% vs. 62.3%; 10v, 72.2% vs. 75.5%; 13v, 81.0% vs.
84.8%; 23v, 85.1% vs. 87.3%) and adults (7v, 43.5% vs.46.5%; 10v, 49.9% vs. 61.1%; 13v, 65.5% vs. 76.3%; 23v,
80.7% vs. 88.7%) [30]. The significant decrease in sero-
type coverage for PCV7 and PCV13 post vaccination
shows the impact of the childhood vaccination program
Table 5 Most common serotypes among pneumococcal meningitis isolates in Germany among adults ≥16 years
(1992/93-2005/06, n = 605; 2007/08-2009/10, n = 523; 2010/11-2012/13, n = 444)
Adults 1992/93-
2005/06
2007/08-
2009/10
2010/11-
2012/13
P values
Serotypes (n) % (n) % (n) % pre PCV7 vs post PCV7+13 pre PCV7 vs post PCV7 post PCV7 vs post PCV13
4 43 7.1 12 2.3 3 0.7 <0.0001↓ 0.0001↓ 0.0644↓
6B 31 5.1 6 1.1 3 0.7 <0.0001↓ 0.0002↓ 0.5189↓
9V 34 5.6 12 2.3 2 0.5 <0.0001↓ 0.0060↓ 0.0270↓
14 48 7.9 14 2.7 8 1.9 <0.0001↓ 0.0001↓ 0.3952↓
18C 17 2.8 13 2.5 9 2.1 0.5094↓ 0.8533↓ 0.6715↓
19F 36 6.0 25 4.8 14 3.3 0.0892↓ 0.4295↓ 0.2510↓
23F 54 8.9 18 3.4 5 1.2 <0.0001↓ 0.0001↓ 0.0198↓
PCV 7 263 43.5 100 19.1 44 9.9 <0.0001↓ <0.0001↓ 0.0001↓
1 10 1.7 15 2.9 9 2.1 0.2918↑ 0.2232↑ 0.5347↓
5 1 0.2 1 0.2 0 0.0 1.0000 1.0000 1.0000
7F 28 4.6 36 6.9 39 9.1 0.0158↑ 0.1212↑ 0.2799↑
PCV10 302 49.9 152 29.1 92 9.4 <0.0001↓ <0.0001↓ 0.0030↓
3 43 7.1 67 12.8 40 9.4 0.0103↑ 0.0017↑ 0.0645↓
6A 33 5.5 28 5.4 8 1.9 0.1283↓ 1.0000 0.0035↓
19A 18 3.0 26 5.0 28 6.6 0.0180↑ 0.0912↑ 0.4007↑
PCV13 396 65.5 273 52.2 168 17.2 <0.0001↓ <0.0001↓ <0.0001↓
2 2 0.3 0 0.0 0 0.0 0.1480↓ 0.5022↓ 1.0000
8 19 3.1 14 2.7 14 3.3 0.7636↓ 0.7246↓ 0.7032↑
9N 14 2.3 15 2.9 13 3.0 0.5245↑ 0.5768↑ 1.0000
10A 22 3.6 26 5.0 17 4.0 0.5154↑ 0.3016↑ 0.4360↓
11A 13 2.1 11 2.1 17 4.0 0.4186↓ 1.0000 0.1256↑
12F 10 1.7 14 2.7 25 5.9 0.0072↑ 0.3013↑ 0.0219↑
15B 6 1.0 16 3.1 13 3.0 0.0080↑ 0.0161↑ 1.0000
17F 6 1.0 3 0.6 3 0.7 0.5530↓ 0.5165↓ 1.0000
20 2 0.3 3 0.6 4 0.9 0.4958↑ 0.6677↑ 0.7091↑
22F 21 3.5 33 6.3 25 5.9 0.0321↑ 0.0351↑ 0.6856↓
33F 10 1.7 10 1.9 8 1.9 0.8463↑ 0.8227↑ 1.0000
PPV23 488 80.7 511 97.7 375 68 <0.0001↑ 0.0146↑ 0.0153↓
6C 3 0.5 15 2.9 9 2.1 0.0023↑ 0.0016↑ 0.5347↓
15C 2 0.3 7 1.3 12 2.8 0.0055↑ 0.0900↑ 0.1634↑
23A 10 1.7 15 2.9 18 4.2 0.0392↑ 0.2232↑ 0.3749↑
23B 3 0.5 11 2.1 41 9.6 <0.0001↑ 0.0272↑ <0.0001
35B 0 0.0 7 1.3 5 1.2 0.0048↑ 0.0045↑ 1.0000
others 66 10.9 50 9.6 52 12.2 0.8668↓ 0.4921↓ 0.2945↑
NVT 84 13.9 105 20.1 137 32.1 <0.0001↑ 0.0065↑ 0.0001↑
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0.000732493). Arrows indicate increasing or decreasing percentage of serotypes post vaccination.
PCV7: serotypes 4, 6B, 9V, 14, 18C, 19F, 23F; PCV10: PCV7 + serotypes 1, 5, 7F; PCV13: PCV10 + serotypes 3, 6A, 19A; PPV23: PCV13 + serotypes 2, 8, 9N, 10A, 11A,
12F, 15B, 17F, 20, 22F, 33F, but without serotyp 6A; NVT: non-vaccine types, i.e. serotypes not included in any of the above mentioned vaccines.
Significant P values are printed in bold.
Imöhl et al. BMC Infectious Diseases  (2015) 15:61 Page 10 of 13on meningitis among children, as well as the resulting
herd protection effect on meningitis among adults [21].
These findings are in line with the literature, as a decline
in coverage following the introduction of pneumococcalconjugate vaccination has been described in other coun-
tries as well [2,24].
In general, the prevalence of antibiotic-resistant pneumo-
coccal isolates continues to increase worldwide [37,38],
Table 6 Serotype coverage (%) of the 7-, 10-, and 13-valent pneumococcal conjugate vaccines (7v, 10v, 13v), the 23-valent
pneumococcal polysaccharide vaccine (23v), and of the serotypes included in the 13- but not in the 7-valent pneumococcal
conjugate vaccine (13vnon7v) among children <16 years and adults ≥16 years (1992/93-2005/06, n = 1, 382; 2007/08-2009/10,
n = 750; 2010/11-2012/13, n = 638)
Children <16 years Adults ≥16 years
Year 7v 10v 13v 13v non 7v 23v 7v 10v 13v 13v non 7v 23v
1992-1993 52.9 52.9 82.4 29.4 64.7 43.8 56.3 64.6 20.8 81.3
1993-1994 54.5 54.5 63.6 9.1 90.9 31.0 35.7 52.4 21.4 69.0
1994-1995 88.9 88.9 100.0 11.1 100.0 31.3 39.6 60.4 29.2 79.2
1995-1996 75.0 75.0 75.0 0.0 87.5 41.9 51.2 67.4 25.6 93.0
1996-1997 41.2 64.7 79.4 38.2 73.5 56.0 60.0 68.0 12.0 76.0
1997-1998 60.6 66.7 72.7 12.1 77.3 45.0 50.0 75.0 30.0 75.0
1998-1999 64.9 73.7 84.2 19.3 93.0 48.0 52.0 72.0 24.0 80.0
1999-2000 75.0 83.9 87.5 12.5 89.3 57.1 64.3 78.6 21.4 96.4
2000-2001 62.3 71.0 78.3 15.9 81.2 51.4 57.1 68.6 17.1 85.7
2001-2002 57.0 68.4 78.5 21.5 89.9 42.2 42.2 53.3 11.1 73.3
2002-2003 65.3 75.0 79.2 13.9 86.1 41.1 50.0 67.9 26.8 76.8
2003-2004 64.1 73.9 84.8 20.7 84.8 44.1 49.2 61.0 16.9 78.0
2004-2005 60.2 68.0 81.6 21.4 82.5 39.4 50.7 70.4 31.0 78.9
2005-2006 65.4 78.8 82.7 17.3 89.4 51.7 51.7 68.3 16.7 88.3
1992/93-2005/06 62.5 72.2 81.0 18.4 85.1 43.5 49.9 65.5 22.0 80.7
(pre PCV7)
2006-2007 47.1 63.6 80.2 33.1 85.1 35.0 46.9 64.4 29.4 80.6
2007-2008 33.3 52.0 65.3 32.0 76.0 21.3 34.4 51.9 30.6 79.2
2008-2009 19.1 43.8 56.2 37.1 73.0 24.4 32.2 56.1 31.7 76.1
2009-2010 15.9 44.4 60.3 44.4 73.0 10.6 19.4 48.1 37.5 67.5
2007/08-2009/10 22.9 46.7 60.4 37.4 74.0 19.1 29.1 52.2 33.1 74.6
(post PCV7)
2010-2011 11.4 21.5 40.5 29.1 55.7 13.4 25.6 49.4 36.0 74.4
2011-2012 5.6 24.1 33.3 27.8 64.8 9.2 22.0 36.9 27.7 67.4
2012-2013 0.0 1.6 11.5 11.5 52.5 6.5 13.7 25.2 18.7 59.0
2010/11-2012/13 6.2 16.0 29.4 23.2 57.2 9.9 20.7 37.8 27.9 67.3
(post PCV13)
pre7 vs. post7+post13 <0.0001 <0.0001 <0.0001 0.0137 0.0004 <0.0001 <0.0001 0.0001 0.0140 0.0130
pre7 vs. post7 <0.0001 0.0010 0.0010 0.0024 0.0539 0.0001 0.0005 0.0065 0.0096 0.1900
post7 vs. post13 0.0529 0.0148 0.0243 0.0887 0.0129 0.1219 0.2328 0.1130 0.3448 0.2637
Corrected for multiple comparisons using the Dunn-Šidák test (β = 0. 001708316).
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nents [39,40]. According to the current CLSI guidelines
[20], different susceptibility breakpoints have to be ap-
plied for penicillin G with regard to meningitis and non-
meningitis cases. All isolates associated with meningitis
that were formerly categorized as intermediate are now
regarded as resistant, which results in higher resistance
rates and should be kept in mind when interpreting sur-
veillance studies on pneumococcal penicillin resistance
[41,42]. The difference concerning the macrolide nonsus-
ceptibility among children and adults in our study can beattributed to the higher resistance rates among children
observed in the years from 2000 to 2007 [43]. The intro-
duction of childhood vaccination has reduced these rates
significantly (p<0.0001), since most resistant isolates were
found among vaccine serotypes. With regard to findings
in other countries, the antibiotic sensitivity of S. pneumo-
niae isolates detected in Germany is still relatively low
[4,6,24,27-29,44].
Based on serotype distribution, antimicrobial suscepti-
bility and theoretical vaccine coverage among pneumo-
coccal meningitis cases in Germany from 1992/93 to
Table 7 Antibiotic susceptibilities of pneumococcal meningitis isolates among children <16 years and adults ≥16 years
in Germany from 1992/93 to 2012/13
Children <16 years Adults ≥16 years CLSI breakpoints (mg/L)
I% R% n I% R% n I R
Penicillin G, meningitis 0.0 7.2 1,317 0.0 7.2 1,731 - ≥0.12
Cefotaxime, meningitis 0.8 0.5 1,317 0.9 0.2 1,729 1 ≥2
Macrolides* 0.1 19.8 1,317 0.1 10.8 1,730 0.5 ≥1
Clindamycin 0.2 5.9 1,316 0.5 5.7 1,730 0.5 ≥1
Tetracycline 0.4 9.2 1,316 0.9 8.9 1,731 2 ≥4
Levofloxacin 0.2 0.3 874 0.2 0.1 1,326 4 ≥8
SXT 6.1 5.7 870 7.1 5.5 1,318 1/19-2/38 ≥4/76
I, intermediately-resistant; R, resistant; n, number of isolates. SXT, trimethoprim-sulfamethoxazole. MIC breakpoints according to CLSI M100-S24, 2014 [20].
*Macrolides: erythromycin or clarithromycin.
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PCV13 on clinical practice. These findings have to be
considered in the context of the serious burden of dis-
ease as Streptococcus pneumoniae represents one of the
most frequent pathogens in acute bacterial meningitis,
often leading to sustained neurological deficits in survi-
vors. In light of the relevance of the clonal and capsular
types for the clinical pathogenicity of pneumococci [45],
our data suggest that the introduction of PCV7 and
PCV13 in the German pediatric immunization program has
had an important influence on the spectrum of pneumo-
coccal meningitis across all ages. It remains to be clarified
whether such differences, and the impact of vaccination
programs, may also contribute to the heterogeneity of
therapeutic responses in acute bacterial meningitis.
Conclusions
The serotype distributions among both children and
adults showed drastic changes, with the vaccine-serotypes
loosing importance. The reduction in prevalence of
vaccine-serotypes among adults clearly suggests a herd-
protection effect. Changes in serotype prevalence must be
continuously monitored to observe future trends concern-
ing pneumococcal meningitis.Competing interests
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